IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
- Mechanism
- Curator reviewed
IGN311 is a humanized monoclonal antibody against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide. Lewis Y is over-expressed in up to 90% of all epithelial cancers and its expression on adult normal tissues is very restricted; hence IGN311 has the potential to target a broad range of carcinomas. IGN311 is designed to exert clinical effects by destruction of tumor cells by activation of effector functions and by selective growth inhibition via functional receptors.
- Primary indication
- Intended for the treatment of various forms of cancer.Curator reviewed
- Code names
- IGN311
Resolves to
What you can answer from here — as of October 01, 2026
Which drugs share a target with IGN311, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account